AstraZeneca - Research-Based BioPharmaceutical Company
WEBKeep up to date with the latest news. At AstraZeneca, we’re committed to diving deep into the root cause of heart failure to determine the changes we need to make in ways we …
AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
WEBMay 21, 2024 · Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade.
Media Centre - AstraZeneca
WEBSep 16, 2024 · Medical releases. AstraZeneca Media centre. The Hub for our Articles, Press Releases and Webcasts & Presentations.
AstraZeneca to acquire Fusion to accelerate the development of …
WEBMar 19, 2024 · AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing ...
AZD1222 vaccine met primary efficacy endpoint in ... - AstraZeneca
WEBNov 23, 2020 · Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a …
AstraZeneca to acquire Icosavax, including potential first-in-class …
WEBDec 12, 2023 · AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform.
Coronavirus (COVID-19) information & research hub - AstraZeneca
WEBFrom the latest news on antibody testing to our ever-developing covid research, learn about our efforts to combat COVID-19.
9M and Q3 2023 results - AstraZeneca
WEB9M and Q3 2023 results. PUBLISHED 9 November 2023. Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
Calquence combination regimen demonstrated statistically …
WEBMay 2, 2024 · Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard ...
Our company - AstraZeneca
WEBWe are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do …
- Some results have been removed